Tissue preparations: clinical reports
Eighteen institute-report reproductions and a separately indexed Sigumir publication. These are source records, not nineteen independently validated trials.
Findings from selected studies
- Glucose in the diabetes subgroup
An institute report describes 22 patients receiving Suprefort and 17 controls with type 2 diabetes. Two-hour glucose was 7.0 mmol/L with Suprefort and 9.4 mmol/L with usual care.
Oral peptide studies and related injection trials
- Oral Pinealon and Vesugen were compared in 170 older men. Working-memory scores were 17.4 with Pinealon, 17.8 with Vesugen and 17.5 with both, versus 12.4 with an active multivitamin control.
- Chitomur in men with prostate symptoms reported higher peak urinary flow after treatment than placebo. In a separate study in women with overactive bladder, urgency improved in both groups. Each report included 50 participants.
- Oral Cerluten with injected Cortexin was compared with Cortexin and usual care in 167 older women. All three groups improved on the study’s psychosomatic severity scale.
- Vladonix in COVID-19 outpatients studied four groups of 12. The moderate-disease combination included Vladonix and two other agents. A separate 15-donor study applied Vladonix and other peptides directly to cultured blood cells.
- Oral Ovagen was reported in 40 adjunct-treatment and 34 usual-care patients. The oral Libidon report compared 48 adjunct-treatment patients and 22 controls. Both reports use shared baseline columns and mark significance against baseline.
- Oral Bronchogen had a 78-person comparison with standard care in chronic bronchitis. The authors report stratified randomization. Placebo and masking were not described.
- Vesugen was compared with untreated observation in 41 men. The original identifies the dose and gives Doppler results. Its route is unspecified.
- Slavinorm was injected in a 108-person double-blind placebo-controlled trial. A related Ventvil trial registration lists 130 planned participants and covers a different injectable preparation for liver disease. Public trial outcomes remain unavailable. A rat tissue-culture study reports a 21% increase in liver explant area index with Ventvil. A 2012 rat surgery paper repeats numerical results from a 2007 EDL patent under different methods.
How to read these reports
The reports below are available through commercial reproductions. Their existence is useful for tracing research, but does not authenticate the original protocol or establish independent peer review. Study dates are distinguished from the dates of later websites and compilations.
Compare treatment groups, baseline differences and co-treatments before interpreting a result. A significant change within one group is not necessarily a significant difference between groups. Small samples and short observation periods leave substantial uncertainty about clinical benefit and safety.
Cerluten ↗
Profile and linked evidence
Sigumir ↗
Profile and linked evidence
Svetinorm ↗
Profile and linked evidence
Ventfort ↗
Profile and linked evidence
Suprefort ↗
Profile and linked evidence
Vladonix ↗
Profile and linked evidence
Endoluten ↗
Profile and linked evidence
Chelohart ↗
Profile and linked evidence
Glandokort ↗
Profile and linked evidence
Gotratix ↗
Profile and linked evidence
Pielotax ↗
Profile and linked evidence
Taxorest ↗
Profile and linked evidence
Bonothyrk ↗
Profile and linked evidence
Visoluten ↗
Profile and linked evidence
Zhenoluten ↗
Profile and linked evidence
Stamakort ↗
Profile and linked evidence
Testoluten ↗
Profile and linked evidence
Tireogen ↗
Profile and linked evidence
Libidon ↗
Profile and linked evidence
Recovered records
Cerluten: clinical report on a tissue-derived preparation
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Tissue-derived mixture / named preparation · Institute report — commercial reproduction
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2006 study/report date, not website publication date
The 2005–2006 report describes attention-test and selected EEG improvements during 10–20 days of adjunctive treatment.
- Population / setting
- 85 patients: 48 adjunctive Cerluten; 37 conventional-care controls. Mixed neurological diagnoses.
- Source reviewed
- Russian report reproduced on a commercial website; population, comparison and reported outcomes checked. Signed original and full protocol not authenticated.
Study limitations
- Random allocation and blinding are not documented. EEG assessment selected more severely affected patients; the findings cannot establish stroke recovery or benefit in healthy people.
- Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
- Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
Reviewed 2026-10-02.
Sigumir: clinical report on a tissue-derived preparation
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Tissue-derived mixture / named preparation · Institute report — commercial reproduction
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2006 study/report date, not website publication date
The 2005–2006 report describes symptom changes over 30–45 days, without substantial radiographic improvement. The English brochure repeats its cohort and percentages under Cartalax; preparation attribution and cohort independence are unresolved.
- Population / setting
- 64 patients: 33 adjunctive Sigumir; 31 controls. Knee osteoarthritis, spinal degeneration or osteoporosis.
- Source reviewed
- Russian report reproduced on a commercial website; population, comparison and reported outcomes checked. Signed original and full protocol not authenticated.
Study limitations
- Reported symptom percentages are difficult to reconcile with the small diagnostic subgroups. Allocation and blinding are unclear. Symptom relief does not establish cartilage regeneration.
- Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
- Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
Reviewed 2026-10-02.
Svetinorm: clinical report on a tissue-derived preparation
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Tissue-derived mixture / named preparation · Institute report — commercial reproduction
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2006 study/report date, not website publication date
Bilirubin was 20.1 µmol/L after adjunctive Svetinorm and 23.6 µmol/L after conventional care. The table marks a change from the shared baseline of 27.1 µmol/L.
Results and tables
Reported findings and study design
47 adults received Svetinorm plus usual care and 38 controls received usual care. The group methods describe two capsules twice daily before meals for 15–20 days.
Population or model 85 patients: 47 adjunctive Svetinorm; 38 controls. Chronic hepatitis or care following radiation/chemotherapy.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Bilirubin | 20.1 ± 0.8 µmol/L with Svetinorm and 23.6 ± 1.4 µmol/L with conventional care. Shared baseline 27.1 ± 1.2 µmol/L. | |
| ALT in the report’s stated units | 43.5 ± 3.5 with Svetinorm and 46.1 ± 3.8 with conventional care. Shared baseline 52.5 ± 4.1. Both arms were marked significant versus baseline. |
The table gives a shared baseline and reports significance against baseline.
Source for these results ↗ · Reviewed 2026-11-16
- Population / setting
- 85 patients: 47 adjunctive Svetinorm; 38 controls. Chronic hepatitis or care following radiation/chemotherapy.
- Source reviewed
- Russian report reproduced on a commercial website; population, comparison and reported outcomes checked. Signed original and full protocol not authenticated.
Study limitations
- A within-group change is not proof of superiority over controls. Mixed diagnoses, co-treatments and incomplete allocation reporting limit interpretation.
- Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
- Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
Reviewed 2026-11-16.
Ventfort: clinical report on a tissue-derived preparation
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Tissue-derived mixture / named preparation · Institute report — commercial reproduction
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2006 study/report date, not website publication date
The 2005–2006 report describes lipid and capillary-fragility outcomes during 10–15 days of adjunctive care.
- Population / setting
- 49 patients: 27 adjunctive Ventfort; 22 controls; ages 52–84, atherosclerosis or senile purpura.
- Source reviewed
- Russian report reproduced on a commercial website; population, comparison and reported outcomes checked. Signed original and full protocol not authenticated.
Study limitations
- The table contains inconsistent sex subtotals. Lipid-table significance is relative to baseline; it does not establish fewer cardiovascular events.
- Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
- Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
Reviewed 2026-10-02.
Suprefort: clinical report on a tissue-derived preparation
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Tissue-derived mixture / named preparation · Institute report — commercial reproduction
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2006 study/report date, not website publication date
In the diabetes subgroup, two-hour glucose was 7.0 mmol/L with Suprefort versus 9.4 mmol/L with usual care. Pancreatic enzyme changes in the separate pancreatitis subgroup were reported as trends.
Results and tables
Reported findings and study design
The group table lists 22 treated and 17 controls with type 2 diabetes, and 12 treated and 8 controls with chronic pancreatitis. The diabetes section describes one 10 mg capsule twice daily before meals for 10 days (20 mg/day). The general methods describe one or two 10 mg capsules twice daily for 15 days (20–40 mg/day).
Population or model 59 patients: pancreatitis 12 treated/8 controls; type-2 diabetes 22 treated/17 controls.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Glucose two hours after challenge, type 2 diabetes subgroup | 7.0 ± 0.8 mmol/L with Suprefort versus 9.4 ± 0.5 mmol/L with usual care. | Table 3 marks p < 0.05 versus usual care. |
| Fasting glucose, type 2 diabetes subgroup | 5.8 ± 0.3 versus 6.6 ± 0.4 mmol/L. Baseline values were 7.9 ± 1.1 and 8.2 ± 0.9 mmol/L respectively. | The report marks significance against baseline for each arm. |
Group sizes are from Table 1. Allocation methods, changes to other medications and the short follow-up limit attribution.
Source for these results ↗ · Reviewed 2026-11-16
- Population / setting
- 59 patients: pancreatitis 12 treated/8 controls; type-2 diabetes 22 treated/17 controls.
- Source reviewed
- Russian Medical Center report, methods and Tables 1–3, PDF pages 74–76.
Study limitations
- Random allocation is asserted for the pancreatitis comparison without a method. Changing glucose-lowering co-treatment complicates attribution. This is not evidence for stopping diabetes medication.
- Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
- Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
Reviewed 2026-11-16.
Vladonix: clinical report on a tissue-derived preparation
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Tissue-derived mixture / named preparation · Institute report — commercial reproduction
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2006 study/report date, not website publication date
In the 76-person institute report, CD4-positive cells were 34.6% after adjunctive oral Vladonix and 30.8% after usual care, compared with a shared 28.5% baseline column.
Results and tables
Reported findings and study design
42 received adjunctive Vladonix and 34 conventional treatment alone. Peripheral-blood immunophenotyping used immunofluorescence. Immunoglobulins were measured by radial immunodiffusion.
Population or model 76 patients: 42 adjunctive Vladonix; 34 controls. Prior low-dose radiation exposure or radiation/chemotherapy.
Dose, route and schedule
One to three oral capsules, two to three times daily before meals for 15–20 days. The report lists 10 mg of thymus extract per capsule. Both arms received conventional care.
Protocol source ↗ · Russian institute-report reproductions, methods and Table 2
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| CD4-positive cells | 34.6% vs 30.8% | Vladonix plus usual care versus usual care. Shared baseline 28.5%. · Vladonix value marked p < 0.05 versus baseline. |
| CD3-positive cells | 55.7% vs 51.9% | Shared baseline 46.5%. · Vladonix value marked p < 0.05 versus baseline. |
| CD4/CD8 ratio | 1.4 vs 1.2 | Shared baseline 1.1. · Vladonix value marked p < 0.05 versus baseline. |
| IgM, IgG, IgA and CD8-positive cells | No significant change marked | Table 2 significance markers do not apply to these rows. |
The report provides a shared baseline column and no clear between-arm test. Its biomarker results do not establish fewer infections or better cancer outcomes.
Source for these results ↗ · Reviewed 2026-11-13
- Population / setting
- 76 patients: 42 adjunctive Vladonix; 34 controls. Prior low-dose radiation exposure or radiation/chemotherapy.
- Source reviewed
- Russian institute-report reproductions, methods and Table 2
Study limitations
- Sex counts differ between prose and table. Immune biomarkers do not establish protection from radiation, fewer infections or improved cancer outcomes.
- Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
- Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
Reviewed 2026-11-13.
Endoluten: clinical report on a tissue-derived preparation
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Tissue-derived mixture / named preparation · Institute report — commercial reproduction
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2011 study/report date, not website publication date
In the dyshormonal myocardial dystrophy subgroup, estradiol was 101.3 pmol/L after Endoluten and 79.1 pmol/L after usual care. The report assessed several diagnoses separately.
Results and tables
Reported findings and study design
163 patients across four diagnoses, 99 receiving adjunctive Endoluten and 64 conventional care. Courses were one to three capsules two to three times daily for 15–30 days.
Population or model 163 patients: 99 adjunctive Endoluten; 64 controls across four diagnostic subgroups.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Estradiol in the dyshormonal myocardial dystrophy subgroup | 101.3 ± 7.2 pmol/L with Endoluten versus 79.1 ± 4.2 pmol/L with conventional care. Shared baseline 65.4 ± 5.2 pmol/L. | Table 2 marks p < 0.05 versus conventional care. |
| Follicle-stimulating hormone in the same subgroup | 46.8 ± 3.9 versus 71.6 ± 6.3 IU/mL, in the source’s printed units. Shared baseline 89.3 ± 3.5. | Table 2 marks p < 0.05 versus conventional care. |
The subgroup outcomes are short-term hormone measurements. The report does not explain the allocation method.
Source for these results ↗ · Reviewed 2026-11-16
- Population / setting
- 163 patients: 99 adjunctive Endoluten; 64 controls across four diagnostic subgroups.
- Source reviewed
- Russian report reproduced on a commercial website; population, comparison and reported outcomes checked. Signed original and full protocol not authenticated.
Study limitations
- Subgroups must not be pooled into one efficacy result. This oral-preparation report cannot inherit long-term Epithalamin mortality findings. The linked page commercially reproduces the report.
- Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
- Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
Reviewed 2026-11-16.
Chelohart: clinical report on a tissue-derived preparation
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Tissue-derived mixture / named preparation · Institute report — commercial reproduction
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2011 study/report date, not website publication date
Angina occurred during exercise testing in 36.4% with Chelohart and 50% with conventional care. Threshold exercise power did not differ significantly between groups.
Results and tables
Reported findings and study design
22 adults received one Chelohart capsule twice daily with meals for 30 days alongside conventional care. Ten controls received conventional therapy alone.
Population or model 32 angina patients: 22 adjunctive Chelohart; 10 controls.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Angina during cycle ergometry | 36.4% with Chelohart versus 50% with conventional care. Shared baseline 68.8%. | The report marks p < 0.05 versus conventional care. |
| Achieving submaximal heart rate | 54.5% versus 40%. Shared baseline 21.9%. | The report marks p < 0.05 versus conventional care. |
| Threshold exercise power | 119.3 ± 4.6 versus 115.2 ± 5.4 in the report’s stated units. | The text reports a nonsignificant between-group difference. |
The report leaves allocation and masking unspecified and gives a shared baseline for the exercise table.
Source for these results ↗ · Reviewed 2026-11-16
- Population / setting
- 32 angina patients: 22 adjunctive Chelohart; 10 controls.
- Source reviewed
- Russian report reproduced on a commercial website; population, comparison and reported outcomes checked. Signed original and full protocol not authenticated.
Study limitations
- A larger numerical improvement is not necessarily a significant between-group difference. Allocation, blinding and complete adverse-event collection need verification from original study documentation.
- Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
- Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
Reviewed 2026-11-16.
Glandokort: clinical report on a tissue-derived preparation
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Tissue-derived mixture / named preparation · Institute report — commercial reproduction
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2011 study/report date, not website publication date
In the adrenal-insufficiency table, plasma aldosterone was 38.5 versus 26.2 pg/mL after adjunctive Glandokort and conventional care, respectively. The subgroup sizes are unclear.
Results and tables
Reported findings and study design
The report mentions 36 patients and separately describes 26 controls. Assignment and subgroup sizes are unclear. The adjunctive schedule was one 10 mg capsule orally with meals twice daily (20 mg/day) for 30 days. The report excluded patients receiving hormone therapy.
Population or model 36 patients described; 26 controls separately stated. Enrollment denominator unresolved.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Plasma aldosterone in the adrenal-insufficiency table | 38.5 ± 1.3 pg/mL with Glandokort versus 26.2 ± 1.6 pg/mL with conventional care. Shared baseline 14.7 ± 1.2 pg/mL. | |
| Cortisol in the prolonged-stress table | 431.4 ± 25.7 versus 311.4 ± 21.4 nmol/L. Shared baseline 287.5 ± 18.5 nmol/L. | |
| ACTH in the prolonged-stress table | 28.6 ± 1.1 versus 17.4 ± 1.3 pg/mL. The table gives no significance mark for ACTH. |
The tables mark aldosterone and cortisol as significant against conventional care. Subgroup sizes and the relationship of the 26 controls to the 36 described patients are unclear.
Source for these results ↗ · Reviewed 2026-11-16
- Population / setting
- 36 patients described; 26 controls separately stated. Enrollment denominator unresolved.
- Source reviewed
- Russian Medical Center report, PDF pages 32–33, methods and hormone tables.
Study limitations
- Resolve enrollment and diagnostic criteria before pooling participants. Hormone-marker changes cannot establish a treatment for nonspecific fatigue.
- Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
- Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
Reviewed 2026-11-16.
Gotratix With Regular Training: 2011 Grip and Jump Study
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Tissue-derived mixture / named preparation · Institute report — commercial reproduction
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · 2011 institute report, reproduced by distributors
At two months, both grip measures and standing long jump improved from baseline in the Gotratix group. Step-test and flexibility changes were nonsignificant.
Results and tables
Reported findings and study design
The Gotratix group gained 6 kg in each handgrip test and 16 cm in standing long jump over two months. The report marked all three changes significant from that group’s baseline.
Former rowers and track-and-field athletes aged 40–65 continued their regular training. The comparison group trained without Gotratix. Endurance was assessed with a modified Harvard step test, and flexibility with a standing forward bend. Testing sessions were two months apart.
Population or model 37 former athletes aged 40–65 in the signed scan, 20 assigned to Gotratix plus training and 17 to training alone. The analyzed denominator is unclear.
Dose, route and schedule
The signed Russian report describes two oral 10 mg capsules twice daily with meals for 30 days (40 mg/day). Both groups continued their usual training.
Protocol source ↗ · Russian report, group procedures and capsule strength
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Right-hand grip | 47 → 53 kg | Training alone: 46 → 47 kg · Gotratix group before vs after: p < 0.05 |
| Left-hand grip | 42 → 48 kg | Training alone: 43 → 45 kg · Gotratix group before vs after: p < 0.05 |
| Standing long jump | 215 → 231 cm | Training alone: 212 → 219 cm · Gotratix group before vs after: p < 0.05 |
| Modified step test | 55 → 58 steps | Training alone: 53 → 57 steps · Change in the Gotratix group was nonsignificant |
| Flexibility | 7.0 → 9.2 cm | Training alone: 6.3 → 7.5 cm · Change in the Gotratix group was nonsignificant |
| Tolerability | The report records no side effects, complications or dependence. | The report gives no systematic adverse-event assessment. |
2011 exercise-test table
| Measure | Gotratix + training, first test | Gotratix + training, second test | Training alone, first test | Training alone, second test |
|---|---|---|---|---|
| Right-hand grip (kg) | 47 ± 2.1 | 53 ± 3.9* | 46 ± 1.4 | 47 ± 1.6 |
| Left-hand grip (kg) | 42 ± 1.7 | 48 ± 1.4* | 43 ± 1.3 | 45 ± 1.8 |
| Standing long jump (cm) | 215 ± 4 | 231 ± 3* | 212 ± 6 | 219 ± 6 |
| Step test (steps) | 55 ± 3.1 | 58 ± 6.8 | 53 ± 6.3 | 57 ± 7.5 |
| Flexibility (cm) | 7.0 ± 1.1 | 9.2 ± 2.1 | 6.3 ± 2.1 | 7.5 ± 1.7 |
Values are reproduced as M ± m. An asterisk marks p < 0.05 against the first test within the same group. The signed scan labels the table as results in men but lists the full study arm sizes.
The report gives no between-group effect estimate, and the numbers analyzed are unclear. The Gotratix and SPORT 5 Plus reports share the study site, dates, tests and nine of ten control-group means and error values. The Gotratix cohort is excluded from the sports participant total because its independence is unverified.
Source for these results ↗ · Reviewed 2026-11-15
- Population / setting
- 37 former athletes aged 40–65 in the signed scan, 20 assigned to Gotratix plus training and 17 to training alone. The analyzed denominator is unclear.
- Source reviewed
- Methods and numerical table checked against the signed Russian scan and both reprints. The treated-arm count differs by edition.
Study limitations
- The signed scan reports 37 participants (20 Gotratix, 17 controls), but its sex counts sum to 27 and the men’s table repeats the full arm sizes. The compiled editions label the Gotratix arm n=22.
- The report describes no randomization or blinding and gives no statistical comparison of changes between groups.
- The institute report has no documented independent peer review. Its short tolerability account cannot establish long-term safety or equivalence to current products.
- The Gotratix and SPORT 5 Plus reports share the study site, dates, tests and nine of ten control-group means and error values. The Gotratix cohort is excluded from the sports participant total because its independence is unverified.
Reviewed 2026-11-15.
Pielotax: clinical report on a tissue-derived preparation
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Tissue-derived mixture / named preparation · Institute report — commercial reproduction
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2011 study/report date, not website publication date
After 30 days, blood urate was 0.44 versus 0.56 mmol/L in men and 0.37 versus 0.48 mmol/L in women, comparing adjunctive Pielotax with conventional treatment.
Results and tables
Reported findings and study design
42 participants with gouty nephropathy: 27 received one to two Pielotax capsules three times daily before meals for 30 days alongside conventional therapy, and 15 received conventional therapy. The report describes random assignment without explaining how it was performed.
Population or model Gouty nephropathy: 27 treated, 15 controls.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Blood urate in men | 0.44 ± 0.02 mmol/L with Pielotax versus 0.56 ± 0.01 mmol/L with conventional care. | |
| Blood urate in women | 0.37 ± 0.03 mmol/L with Pielotax versus 0.48 ± 0.02 mmol/L with conventional care. | |
| Residual nitrogen | 27.1 ± 0.4 mmol/L with Pielotax versus 30.5 ± 0.6 mmol/L with conventional care. | The table marks p < 0.05 versus conventional care. |
The report measured short-term laboratory markers and gives no detailed adverse-event assessment.
Source for these results ↗ · Reviewed 2026-11-16
- Population / setting
- Gouty nephropathy: 27 treated, 15 controls.
- Source reviewed
- English compilation, PDF pages 43 onward; selected report text/tables checked. Russian original not reconciled.
Study limitations
- Sequence generation, concealment and long-term outcomes remain unresolved. Laboratory-marker changes do not establish prevention of kidney failure.
- Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
- Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
Reviewed 2026-11-16.
Taxorest: clinical report on a tissue-derived preparation
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Tissue-derived mixture / named preparation · Institute report — commercial reproduction
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2011 study/report date, not website publication date
Forced expiratory vital capacity was 3,940.5 mL with adjunctive Taxorest and 3,225.6 mL with conventional care. Significance was marked against the shared baseline.
Results and tables
Reported findings and study design
52 smokers with chronic bronchitis in remission, 31 receiving adjunctive Taxorest and 21 conventional therapy alone. The studied oral schedule was one 10 mg capsule with meals twice daily (20 mg/day) for 30 days.
Population or model 52 smokers with bronchitis: 31 treated, 21 controls.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Forced expiratory vital capacity | 3,940.5 ± 123.6 mL with Taxorest versus 3,225.6 ± 148.2 mL with conventional care. Shared baseline 2,767.8 ± 134.7 mL. | |
| Vital capacity | 4,220.7 ± 243.1 mL with Taxorest versus 3,876.5 ± 215.4 mL with conventional care. Shared baseline 3,654.1 ± 231.9 mL. | |
| Total lung capacity | 5,246.1 ± 223.6 versus 5,075.4 ± 211.6 mL. The table gives no significance mark for total lung capacity. |
The table marks changes against the shared baseline. It gives no between-group statistical test.
Source for these results ↗ · Reviewed 2026-11-16
- Population / setting
- 52 smokers with bronchitis: 31 treated, 21 controls.
- Source reviewed
- Russian Medical Center report, PDF pages 80–81, methods and spirometry table.
Study limitations
- Allocation and blinding are not established. Within-group improvement cannot establish superiority or protection against smoking-related disease.
- Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
- Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
Reviewed 2026-11-16.
Application of bioregulating therapy in complex treatment of temporomandibular joint diseases in people of elderly and senile age
Named tissue-derived preparation · Journal publication
A. K. Iordanishvili, V. V. Samsonov, L. N. Soldatova, A. A. Polens, G. A. Ryzhak · Adv Gerontol. 2012;25(1):181–186. PMID 22708467
The indexed abstract describes adjunctive Sigumir in older patients with temporomandibular joint disease. Full clinical appraisal remains pending.
Results and tables
Reported findings and study design
62 older patients with temporomandibular-joint disease; Sigumir as part of prosthetic, functional and pharmacological care.
Population or model 62 older patients with temporomandibular joint diseases
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Pain, mouth opening and chewing | Improvement reported | No numerical outcome changes or comparison-group counts supplied |
Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- 62 older patients with temporomandibular joint diseases
- Source reviewed
- PubMed citation and abstract checked; full paper not reviewed.
Study limitations
- The abstract does not establish allocation, blinding, arm sizes or an effect estimate. Full methods remain to be acquired.
- This is a distinct joint-disease report, not replication of every claim in the earlier institute report.
Reviewed 2026-10-02.
Bonothyrk: institute clinical report (commercially hosted translation)
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Oral calf parathyroid tissue polypeptide complex · Institute report — commercial reproduction
Format: PDF · Reviewed: Report reproduction reviewed
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute-attributed report, 2011; commercially hosted brochure pp. 9–10
The 33-person report gives bone mineral density loss categories three months after treatment. The printed category percentages conflict with the stated group sizes.
Results and tables
Reported findings and study design
33 women aged 47–56 with climacteric symptoms and reduced bone mineral density. Twenty took two 10 mg capsules twice daily (40 mg/day) for 30 days. Thirteen took no intervention aimed at raising bone density. Densitometry was performed before treatment and three months after the course.
Population or model 33 women aged 47–56: 20 preparation, 13 controls
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Reported category of 15–20% bone mineral density loss | At three months, 94.7% in the Bonothyrk group and 90.5% in controls, as printed. The table gives a shared baseline of 90.5%. | |
| Reported category of 20–25% bone mineral density loss | At three months, 5.3% with Bonothyrk and 14.4% in controls, as printed. |
The table percentages cannot be reconciled with the stated group sizes and control percentages sum to 104.9%. The category figures do not provide a reliable between-group effect on bone density.
Source for these results ↗ · Reviewed 2026-11-16
- Population / setting
- 33 women aged 47–56: 20 preparation, 13 controls
- Source reviewed
- Russian Medical Center report reproduction, methods and densitometry table.
Study limitations
- The signed original has not been authenticated. Allocation and masking are not described. The entry criterion and reported baseline categories are inconsistent. The control percentages do not sum to 100%.
- The report provides no fracture outcomes or interpretable between-group change in bone mineral density.
Reviewed 2026-11-16.
Visoluten: institute clinical report (commercially hosted translation)
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Tissue-derived mixture / named preparation · Institute report — commercial reproduction
Format: PDF · Reviewed: Report reproduction reviewed
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute-attributed report, 2011; commercially hosted brochure pp. 17–19
The report describes visual-acuity and retinal electrophysiology changes during adjunctive care.
- Population / setting
- 49 patients: 29 adjunctive preparation, 20 conventional-care controls
- Source reviewed
- Brochure PDF pp. 17–19: methods/results text checked; selected population/table pages visually inspected. This is a provenance check, not authentication of the institute original.
Study limitations
- Commercial reproduction: signed original, protocol and translation accuracy have not been authenticated.
- Random division is asserted without sequence or concealment details. Percentages and eye-versus-patient denominators need original data.
- Short follow-up and incomplete adverse-event methods do not establish safety; independent replication and present-day product equivalence remain unverified.
Reviewed 2026-10-05.
Zhenoluten: institute clinical report (commercially hosted translation)
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Tissue-derived mixture / named preparation · Institute report — commercial reproduction
Format: PDF · Reviewed: Report reproduction reviewed
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute-attributed report, 2011; commercially hosted brochure pp. 34–35
The report describes symptom and hormone changes during adjunctive treatment.
- Population / setting
- 67 women: 39 with climacteric symptoms and 28 with early ovarian insufficiency; four comparison groups
- Source reviewed
- Brochure PDF pp. 34–35: methods/results text checked; selected population/table pages visually inspected. This is a provenance check, not authentication of the institute original.
Study limitations
- Commercial reproduction: signed original, protocol and translation accuracy have not been authenticated.
- Group-specific denominators are unclear. The translated identity paragraph says triceps tissue despite an ovarian target; the original formulation must be checked.
- Short follow-up and incomplete adverse-event methods do not establish safety; independent replication and present-day product equivalence remain unverified.
Reviewed 2026-10-05.
Stamakort: institute clinical report (commercially hosted translation)
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Tissue-derived mixture / named preparation · Institute report — commercial reproduction
Format: PDF · Reviewed: Report reproduction reviewed
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute-attributed report, 2011; commercially hosted brochure pp. 56–57
Fasting total gastric acidity was 37.1 mmol/L after Stamakort plus conventional therapy versus 31.4 mmol/L with conventional therapy alone.
Results and tables
Reported findings and study design
47 adults with chronic gastritis, 30 receiving adjunctive Stamakort and 17 receiving conventional therapy. The report describes random assignment without a method. It lists one or two 10 mg capsules orally three times daily before meals for 30 days (30–60 mg/day).
Population or model 47 patients with chronic gastritis: 30 adjunctive preparation, 17 conventional-care controls
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Fasting total gastric acidity | 37.1 ± 1.8 mmol/L with Stamakort versus 31.4 ± 2.4 with usual care. Pretreatment values were 22.6 ± 1.7 and 24.2 ± 2.1, respectively. | Table 2 marks p < 0.05 versus usual care. |
| Free hydrochloric acid | 19.2 ± 1.5 versus 15.9 ± 1.3 mmol/L after treatment. | Both arms are marked against baseline. No between-group significance mark is printed. |
The report gives no masking, prespecified clinical endpoint or systematic harms assessment.
Source for these results ↗ · Reviewed 2026-11-16
- Population / setting
- 47 patients with chronic gastritis: 30 adjunctive preparation, 17 conventional-care controls
- Source reviewed
- Russian Medical Center report, methods and Tables 1–2, PDF pages 69–70.
Study limitations
- Commercial reproduction: signed original, protocol and translation accuracy have not been authenticated.
- Random allocation is asserted without a method or concealment details; background therapy and surrogate outcomes limit interpretation.
- Short follow-up and incomplete adverse-event methods do not establish safety; independent replication and present-day product equivalence remain unverified.
Reviewed 2026-11-16.
Testoluten: institute clinical report (commercially hosted translation)
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Tissue-derived mixture / named preparation · Institute report — commercial reproduction
Format: PDF · Reviewed: Report reproduction reviewed
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute-attributed report, 2011; commercially hosted brochure pp. 68–70
The report describes hormone and self-reported symptom changes with adjunctive treatment.
- Population / setting
- 36 men aged 47–65: 22 adjunctive preparation, 14 nonhormonal-care controls
- Source reviewed
- Brochure PDF pp. 68–70: methods/results text checked; selected population/table pages visually inspected. This is a provenance check, not authentication of the institute original.
Study limitations
- Commercial reproduction: signed original, protocol and translation accuracy have not been authenticated.
- Allocation and blinding are unclear; testosterone units differ between the table and prose, and fertility benefit was not established.
- Short follow-up and incomplete adverse-event methods do not establish safety; independent replication and present-day product equivalence remain unverified.
Reviewed 2026-10-05.
Tireogen: institute clinical report (commercially hosted translation)
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Tissue-derived mixture / named preparation · Institute report — commercial reproduction
Format: PDF · Reviewed: Report reproduction reviewed
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute-attributed report, 2006; commercially hosted brochure pp. 73–74
The report describes symptom and thyroid-hormone changes during adjunctive care.
- Population / setting
- 25 treated patients and 19 controls with primary hypothyroidism; report dates November 2005–January 2006
- Source reviewed
- Brochure PDF pp. 73–74: methods/results text checked; selected population/table pages visually inspected. This is a provenance check, not authentication of the institute original.
Study limitations
- Commercial reproduction: signed original, protocol and translation accuracy have not been authenticated.
- Concurrent thyroid treatment is inadequately specified. This cannot establish a substitute for thyroid-hormone replacement or confirm durable thyroid restoration.
- Short follow-up and incomplete adverse-event methods do not establish safety; independent replication and present-day product equivalence remain unverified.
Reviewed 2026-10-05.
Libidon: clinical report reproduced in the Russian institute-report collection (2011)
Prostate-derived peptide mixture · Institute report — commercial reproduction
Format: Russian PDF brochure · Reviewed: Methods and urinary flow tables checked in the Russian reproduction
Medical Center, St Petersburg Institute of Bioregulation and Gerontology (attributed in reproduction) · Commercial brochure, PDF pages 47–50; institute original unauthenticated
In the reproduced Libidon report, mean urinary flow at 30 days was 23.5 vs 19.8 mL/s in chronic prostatitis and 17.5 vs 14.2 mL/s in benign prostatic hyperplasia with adjunctive Libidon versus usual care.
Results and tables
Reported findings and study design
48 men received adjunctive Libidon (28 chronic prostatitis, 20 benign prostatic hyperplasia). Another 22 received usual care. Used uroflowmetry, symptoms and ultrasound.
Population or model 48 treated men aged 38–65 (28 chronic prostatitis, 20 benign prostatic hyperplasia); 22 controls described separately; full denominator reconciliation pending
Dose, route and schedule
One 10 mg oral capsule twice daily with meals for 30 days alongside usual treatment. The comparator received usual treatment alone.
Protocol source ↗ · Russian institute-report reproduction, methods and Tables 1–3
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Chronic prostatitis · mean urinary flow | 23.5 vs 19.8 mL/s | Adjunctive Libidon versus usual care after 30 days. Shared baseline column 17.3 mL/s. · Adjunct arm marked p < 0.05 versus baseline. |
| Benign prostatic hyperplasia · mean urinary flow | 17.5 vs 14.2 mL/s | Shared baseline column 11.3 mL/s. · Adjunct arm marked p < 0.05 versus baseline. |
| Peak urinary flow | 26.5 vs 24.4 mL/s in prostatitis and 20.5 vs 18.2 mL/s in hyperplasia | Adjunctive Libidon versus usual care. · The report marks neither row as significant relative to baseline. |
| Reported adverse effects | None described | Systematic monitoring and harms by arm are unavailable. |
Tables 2–3 · uroflowmetry
| Measure | Baseline column | Usual care | Usual care + Libidon |
|---|---|---|---|
| Prostatitis · mean flow (mL/s) | 17.3 ± 1.2 | 19.8 ± 1.6 | 23.5 ± 2.4* |
| Prostatitis · peak flow (mL/s) | 22.1 ± 2.3 | 24.4 ± 2.1 | 26.5 ± 3.1 |
| Hyperplasia · mean flow (mL/s) | 11.3 ± 1.2 | 14.2 ± 1.4 | 17.5 ± 1.6* |
| Hyperplasia · peak flow (mL/s) | 16.1 ± 2.3 | 18.2 ± 1.9 | 20.5 ± 2.1 |
Asterisks indicate p < 0.05 versus baseline. The report does not identify the type of ± term.
The tables give a single baseline per diagnostic group and do not state comparator subgroup counts. The significance markers do not test superiority over usual care.
Source for these results ↗ · Reviewed 2026-11-13
- Population / setting
- 48 treated men aged 38–65 (28 chronic prostatitis, 20 benign prostatic hyperplasia); 22 controls described separately; full denominator reconciliation pending
- Source reviewed
- Russian institute-report reproduction, methods and Tables 1–3
Study limitations
- The signed original and protocol have not been authenticated.
- Allocation and blinding are not established; diagnostic subgroups, 22 separately described controls and symptom-specific denominators require reconciliation.
- Concurrent treatment prevents attribution to Libidon alone. No equivalence to Prostatilen or Prostamax is established.
Reviewed 2026-11-13.
What is still missing?
Signed Russian originals, complete protocols, allocation procedures, participant flow, prespecified endpoints, adverse-event collection and independent replication remain recovery priorities. Translation and transcription errors require comparison with the original scans.
Visoluten, Bonothyrk, Stamakort, Testoluten, Zhenoluten and Tireogen now have brochure-level report checks. Their signed originals remain unauthenticated. Chitomur has two indexed studies with Russian article reproductions that include methods and numerical tables. The original journal pages would help resolve inconsistencies in the reproduced reporting. The Libidon report now includes oral exposure and uroflowmetry results, with a separate scan for source comparison. Related preparations cannot fill these gaps by association.
Peptide evidence map · Bibliography and PDF sources · Citable research library